Automated Measurement of Effective Radiation Dose by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

BACKGROUND/OBJECTIVES

Calculating the radiation dose from CT in 18F-PET/CT examinations poses a significant challenge. The objective of this study is to develop a deep learning-based automated program that standardizes the measurement of radiation doses.

METHODS

The torso CT was segmented into six distinct regions using TotalSegmentator. An automated program was employed to extract the necessary information and calculate the effective dose (ED) of PET/CT. The accuracy of our automated program was verified by comparing the EDs calculated by the program with those determined by a nuclear medicine physician (n = 30). Additionally, we compared the EDs obtained from an older PET/CT scanner with those from a newer PET/CT scanner (n = 42).

RESULTS

The CT ED calculated by the automated program was not significantly different from that calculated by the nuclear medicine physician (3.67 ± 0.61 mSv and 3.62 ± 0.60 mSv, respectively, p = 0.7623). Similarly, the total ED showed no significant difference between the two calculation methods (8.10 ± 1.40 mSv and 8.05 ± 1.39 mSv, respectively, p = 0.8957). A very strong correlation was observed in both the CT ED and total ED between the two measurements (r2 = 0.9981 and 0.9996, respectively). The automated program showed excellent repeatability and reproducibility. When comparing the older and newer PET/CT scanners, the PET ED was significantly lower in the newer scanner than in the older scanner (4.39 ± 0.91 mSv and 6.00 ± 1.17 mSv, respectively, p < 0.0001). Consequently, the total ED was significantly lower in the newer scanner than in the older scanner (8.22 ± 1.53 mSv and 9.65 ± 1.34 mSv, respectively, p < 0.0001).

CONCLUSIONS

We successfully developed an automated program for calculating the ED of torso 18F-PET/CT. By integrating a deep learning model, the program effectively eliminated inter-operator variability.

Revising and exploring the variations in methodologies for establishing the diagnostic reference levels for paediatric PET/CT imaging

PET-computed tomography (PET/CT) is a hybrid imaging technique that combines anatomical and functional information; to investigate primary cancers, stage tumours, and track treatment response in paediatric oncology patients. However, there is debate in the literature about whether PET/CT could increase the risk of cancer in children, as the machine is utilizing two types of radiation, and paediatric patients have faster cell division and longer life expectancy. Therefore, it is essential to minimize radiation exposure by justifying and optimizing PET/CT examinations and ensure an acceptable image quality. Establishing diagnostic reference levels (DRLs) is a crucial quantitative indicator and effective tool to optimize paediatric imaging procedures. This review aimed to distinguish and acknowledge variations among published DRLs for paediatric patients in PET/CT procedures. A search of relevant articles was conducted using databases, that is, Embase, Scopus, Web of Science, and Medline, using the keywords: PET-computed tomography, computed tomography, PET, radiopharmaceutical, DRL, and their synonyms. Only English and full-text articles were included, with no limitations on the publication year. After the screening, four articles were selected, and the review reveals different DRL approaches for paediatric patients undergoing PET/CT, with primary variations observed in patient selection criteria, reporting of radiation dose values, and PET/CT equipment. The study suggests that future DRL methods for paediatric patients should prioritize data collection in accordance with international guidelines to better understand PET/CT dose discrepancies while also striving to optimize radiation doses without compromising the quality of PET/CT images.

Combined FDG PET/MRI versus Standard-of-Care Imaging in the Evaluation of Cardiac Sarcoidosis

PURPOSE

To compare combined cardiac fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/MRI with standard-of-care evaluation using cardiac MRI, 18F-FDG PET/CT, and SPECT perfusion imaging in suspected cardiac sarcoidosis (CS) with respect to radiation dose, imaging duration, and diagnostic test performance.

MATERIALS AND METHODS

Consecutive patients with suspected CS undergoing clinical evaluation with cardiac 18F-FDG PET/CT and gated rest technetium 99m sestamibi SPECT perfusion imaging were prospectively recruited between November 2017 and May 2021 for parallel assessment with combined cardiac 18F-FDG PET/MRI on the same day (ClinicalTrials.gov identifier, NCT03356756). Total effective radiation dose and imaging duration were compared between approaches (combined cardiac PET/MRI vs separate cardiac MRI, PET/CT, and SPECT). MRI findings were initially interpreted without PET data, and then PET and late gadolinium enhancement images were fused and interpreted together. Final diagnosis of CS was established using Japanese Ministry of Health and Welfare guidelines.

RESULTS

Forty participants (mean age, 54 years ± 14 [SD]; 26 [65%] male participants) were included, 14 (35%) with a final diagnosis of CS. Compared with separate cardiac MRI, PET/CT, and SPECT perfusion imaging, combined cardiac PET/MRI had 52% lower total radiation dose (8.0 mSv ± 1.2 vs 16.8 mSv ± 1.6, P < .001) and 43% lower total imaging duration (122 minutes ± 15 vs 214 minutes ± 26, P < .001). Combined PET/MRI had the highest area under the curve for diagnosis of CS (0.84) with 96% specificity and 71% sensitivity for colocalized FDG uptake and late gadolinium enhancement in a pattern typical for CS.

CONCLUSION

In the evaluation of suspected CS, combined cardiac 18F-FDG PET/MRI had a lower radiation dose, shorter imaging duration, and higher diagnostic performance compared with standard-of-care imaging.Clinical trial registration no. NCT03356756Keywords: Cardiac Sarcoidosis, 18F-FDG PET/MRI, 18F-FDG PET/CT, SPECT Perfusion Imaging, Cardiac MRI, Standard-of-Care Imaging Supplemental material is available for this article. © RSNA, 2023.

A systematic review and meta-analysis on the radiation dose of computed tomography in hybrid nuclear medicine imaging

BACKGROUND

While diagnostic reference levels (DRLs) are well-established for the radiopharmaceutical part, published DRLs for the CT component of positron emission tomography/computed tomography (PET/CT) and single photon emission computed tomography/computed tomography (SPECT/CT) are limited. This systematic review and meta-analysis provides an overview of the different objectives of CT in hybrid imaging and summarizes reported CT dose values for the most common PET/CT and SPECT/CT examinations. Also, an overview of already proposed national DRLs is given.

METHODS

A systematic literature search was performed to identify original articles reporting CT dose index volume (CTDIvol), dose-length product (DLP) and/or national DRLs for the most frequently performed PET/CT and/or SPECT/CT examinations. Data were grouped according to the clinical objective: diagnostic (D-CT), anatomical localisation (AL-CT) or attenuation correction (AC-CT) CT. Random-effects meta-analyses were conducted.

RESULTS

Twenty-seven articles were identified of which twelve reported national DRLs. For brain and tumour PET/CT imaging, CTDIvol and DLP values were higher for a D-CT (brain: 26.7 mGy, 483 mGy cm; tumour: 8.8 mGy, 697 mGy cm) than for an AC/AL-CT (brain: 11.3 mGy, 216 mGy cm; tumour: 4.3 mGy, 419 mGy cm). Similar conclusions were found for bone and parathyroid SPECT/CT studies: D-CT (bone: 6.5 mGy, 339 mGy cm; parathyroid: 15.1 mGy, 347 mGy cm) results in higher doses than AL-CT (bone: 3.8 mGy, 156 mGy cm; parathyroid: 4.9 mGy, 166 mGy cm). For cardiac (AC-CT), mIBG/octreotide, thyroid and post-thyroid ablation (AC/AL-CT) SPECT/CT pooled mean CTDIvol (DLP) values were 1.8 mGy (33 mGy cm), 4.6 mGy (208 mGy cm), 3.1 mGy (105 mGy cm) and 4.6 mGy (145 mGy cm), respectively. For all examinations, high variability in nuclear medicine practice was observed.

CONCLUSION

The large variation in CT dose values and national DRLs highlights the need for optimisation in hybrid imaging and justifies the clinical implementation for nuclear medicine specific DRLs.

Ultra-low-dose CT reconstructed with the artificial intelligence iterative reconstruction algorithm (AIIR) in 18F-FDG total-body PET/CT examination: a preliminary study

PURPOSE

To investigate the feasibility of ultra-low-dose CT (ULDCT) reconstructed with the artificial intelligence iterative reconstruction (AIIR) algorithm in total-body PET/CT imaging.

METHODS

The study included both the phantom and clinical parts. An anthropomorphic phantom underwent CT imaging with ULDCT (10mAs) and standard-dose CT (SDCT) (120mAs), respectively. ULDCT was reconstructed with AIIR and hybrid iterative reconstruction (HIR) (expressed as ULDCT-AIIR_phantom and ULDCT-HIR_phantom), respectively, and SDCT was reconstructed with HIR (SDCT-HIR_phantom) as control. In the clinical part, 52 patients with malignant tumors underwent the total-body PET/CT scan. ULDCT with AIIR (ULDCT-AIIR) and HIR (ULDCT-HIR), respectively, was reconstructed for PET attenuation correction, followed by the SDCT reconstructed with HIR (SDCT-HIR) for anatomical location. PET/CT images' quality was qualitatively assessed by two readers. The CT_mean, as well as the CT standard deviation (CT_sd), SUV_max, SUV_mean, and the SUV standard deviation (SUV_sd), was recorded. The signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were calculated and compared.

RESULTS

The image quality of ULDCT-HIR_phantom was inferior to the SDCT-HIR_phantom, but no significant difference was found between the ULDCT-AIIR_phantom and SDCT-HIR_phantom. The subjective score of ULDCT-AIIR in the neck, chest and lower limb was equivalent to that of SDCT-HIR. Besides the brain and lower limb, the change rates of CT_mean in thyroid, neck muscle, lung, mediastinum, back muscle, liver, lumbar muscle, first lumbar spine and sigmoid colon were -2.15, -1.52, 0.66, 2.97, 0.23, 8.91, 0.06, -4.29 and 8.78%, respectively, while all CT_sd of ULDCT-AIIR was lower than that of SDCT-HIR. Except for the brain, the CNR of ULDCT-AIIR was the same as the SDCT-HIR, but the SNR was higher. The change rates of SUV_max, SUV_mean and SUV_sd were within [Formula: see text] 3% in all ROIs. For the lesions, the SUV_max, SUV_sd and TBR showed no significant difference between PET-AIIR and PET-HIR.

CONCLUSION

The SDCT-HIR could not be replaced by the ULDCT-AIIR at date, but the AIIR algorithm decreased the image noise and increased the SNR, which can be implemented under special circumstances in PET/CT examination.

Reduced-Dose Full-Body CT in Lymphoma Follow-up: A Pilot Study

BACKGROUND

How to reduce the radiation dose received from full-body CT scans during the follow-up of lymphoma patients is a concern.

OBJECTIVE

The aim of the study was to investigate the image quality and radiation dose of reduced-dose full-body computerized tomography (CT) in lymphoma patients during the follow-up.

METHODS

121 patients were included and divided into conventional CT group (group 1, 120-kVp, n = 61) or reduced-dose CT group (group 2, 100-kVp combined dual-energy CT (DECT), n = 60). 140-kVp polychromatic images and 70-keV monochromatic images were reconstructed from DECT. The abdominal virtual non-enhanced (VNE) images were reconstructed from monochromatic images. Two radiologists rated the overall image quality with a five-point scale and graded the depiction of lesions using a four-point scale. The objective image quality was evaluated using image noise, signal-to-noise ratio, and contrast-to-noise ratio. The radiation dose and image quality were compared between the groups.

RESULTS

The comparable subjective image quality was observed between 70-keV and 120-kVp images in the neck, while 120-kVp images showed better objective image quality. 70-keV images showed better objective image quality in the chest. While the subjective image quality of abdominal VNE images was inferior to that of true non-enhanced images, the improved objective image quality was observed in VNE images. In the abdominal arterial phase, similar subjective image quality was observed between the groups. Abdominal 70-keV images in the arterial phase showed improved objective image quality. Similar image quality was obtained in the abdominal venous phase between the groups. The effective radiation dose in group 2 showed a significant reduction.

CONCLUSION

The application of reduced-dose full-body CT can significantly reduce the radiation dose for lymphoma patients during the follow-up while maintaining or improving the image quality.

National Diagnostic Reference Level (DRL) for nuclear medicine computed tomography-positron emission tomography hybrid imaging studies for kuwait population: second phase dose audit-2019

OBJECTIVE

Diagnostic reference levels (DRLs) for CT part of positron emission tomography-CT (PET-CT) examinations are limited. The study was aiming to execute the second phase of the national DRL in support of optimisation and dose reduction in State of KW.

METHODS

In this multicentre collaborative PET-CT study, oncology patient data were exclusively collected due to the National MOH Ethical Committee recommendation and limitation of the other studies. Median, Mean, SD, 75th, 25th percentiles as well as whole body (WB) effective dose (ED) were calculated. The study was UK-IPEM-based methodology and it was the second phase of the study in Kuwait.

RESULTS

Half body (HB) and WB scans were 65 and 35% of the total enterers (309). The third quartile dose-length product (DLP) (mGy x cm) and volumetric CT dose index (mGy) values for the HB (537, 5) were higher than the UK NDRL (400, 4.3) but were lower than the Swiss NDRL (620, 6) and the France NDRL (762, 7.7). Comparatively, the proposed NDRLs for the WB (684, 4.1) were lower than Swiss National Data (720, 5.0) though, the Swiss had about 5000 (HB) & 706 (WB), the UK had 370 (HB) and France had 1000 (HB) entries. Calculated ED varied from 4.1 to 10.2 mSv, (mean values = 6.9 mSv) for HB and from 2.6 to 7 mSv (mean value = 4.6 mSv).

CONCLUSIONS

There was 9.1% improvement in NDRL for 2019, compared to 2018, but there is a continuous need for improving NDRL.

ADVANCES IN KNOWLEDGE

Data provided a trend of NDRL that is served as a national data bank for continuous optimisation.

Assessment of Effective Dose Received in Various Computed Tomography Protocols and Factors Affecting It

PURPOSE OF STUDY

The purpose of the study was to evaluate the effect of patient characteristics and equipment-related factors on the computed tomography (CT) dose received by patients from positron emission tomography-CT (PET-CT) using system-generated dose-length product (DLP) values and also to check the effective dose (ED) received from various CT protocols at our institute.

MATERIALS AND METHODS

This retrospective study included 78 adult patients who underwent F-18 fluorodeoxyglucose whole-body PET-CT and were divided into three groups based on the area of primary cancerous lesion. In Group A, we had 44 patients who underwent PET-CT (head-and-neck protocol), in Group B, we had 24 patients who underwent PET-CT (whole body with brain protocol), and in Group C, we had 10 patients who underwent PET-CT (pelvis protocol). All of the patients under the study are of South Asian ethnicity. A majority of patients 53.85% were males and remaining 46.15% were females. The product of conversion factor (k-coefficient), as described in "American Association of Physicists in Medicine Report No. 96" and DLP value generated by the scanner, was used to calculate the ED. Moreover, we also performed regression analysis to check relation between body weight, height, scan range, tube current, Volume computed tomography dose index (CTDIvol), DLP, and ED.

RESULTS

The regression analysis shows that scan range, patient height, weight, tube current, and DLP were significantly correlated with ED (P < 0.05 for all). Moreover, the DLP and conversion factor method estimated the ED from various groups. Patients under Group A (head-and-neck protocol), Group B (whole body with brain protocol), Group C (pelvis protocol) received an average ED of 22.45 mSv, 22.40 mSv, and 21.24 mSv, respectively.

CONCLUSION

ED from CT component of PET-CT can be assessed as the product of scanner-generated DLP and conversion factor for selected range. Moreover, body weight, scan range, and tube current had an independent significant effect on ED received from CT.

Hybrid Imaging in Evaluation of Abdominal Sarcoidosis

OBJECTIVE

To determine the prevalence of abdominal involvement, distribution pattern and evaluate role of hybrid molecular imaging in patients with abdominal sarcoidosis.

METHODS

Between January 2010 and December 2011, 98 patients with chronic sarcoidosis and presence of prolonged symptoms or other findings suggestive of active disease were referred to FDG PET/CT examination. Active disease was found in 82 patients, and they all were screened for the presence of abdominal sarcoidosis on FDG PET/CT. All patients also underwent MDCT and assessment of serum ACE level. Follow up FDG PET/CT examination was done 12.3±5.4 months after the baseline.

RESULTS

Abdominal sarcoidosis was present in 31/82 patients with active sarcoidosis. FDG uptake was present in: retroperitoneal lymph nodes (77%), liver (26%), spleen (23%), adrenal gland (3%). Majority of patients had more than two locations of disease. Usually thoracic disease was spread into the extrathoracic localizations, while isolated abdominal sarcoidosis was present in 10% of patients. After first FDG PET/CT examination therapy was changed in all patients. Eleven patients came to the follow up examination where SUVmax significantly decreased in the majority of them. Three patients had total remission, three had absence of abdominal disease but discrete findings in thorax and others had less spread disease. ACE levels did not correlate with SUVmax level.

CONCLUSION

FDG PET/CT can be a useful tool for detection of abdominal sarcoidosis and in the evaluation of therapy response in these patients. Awareness of the presence of intra-abdominal sarcoidosis is important in order to prevent long-standing unrecognized disease.

CT protocol optimisation in PET/CT: a systematic review

Purpose

Currently, no consistent guidelines for CT scans used within PET/CT examinations are available. This systematic review provides an up-to-date overview of studies to answer the following questions: What are the specific CT protocols used in PET/CT? What are the possible purposes of requiring a CT study within a PET/CT scan? Is the CT protocol obtained from a dosimetric optimisation study?

Materials and method

PubMed/MEDLINE, Cochrane Library, Embase and Scopus were systematically searched for relevant studies in accordance with the PRISMA statement. The literature search was conducted from January 2007 until June 2019. Data derived from studies were standardized in order to reduce possible biases, and they were divided into clinically homogeneous subgroups (adult, child or phantom). Subsequently, we divided the CT protocol intents into 3 types (anatomic localization only, attenuation correction only and diagnostic purpose). A narrative approach was used to summarise datasets and to investigate their heterogeneity (due to medical prescription methodology) and their combination in multiseries CT protocols. When weighted computed tomography dose index (CTDI_w) was available, we calculated the volumetric computed tomography dose index (CTDI_vol) using the pitch value to make the results uniform. Eventually, the correlation between protocol intents and CTDI_vol values was obtained using a Kruskal–Wallis one-way ANOVA statistical test.

Result

Starting from a total of 1440 retrieved records, twenty-four studies were eligible for inclusion in addition to two large multicentric works that we used to compare the results. We analyzed 87 CT protocols. There was a considerable range of variation in the acquisition parameters: tube current–time product revealed to have the most variable range, which was 10–300 mAs for adults and 10–80 mAs for paediatric patients. Seventy percent of datasets presented scans acquired with tube current modulation, 9% used fixed tube current and in 21% of them, this information was not available. Dependence between mean CTDI_vol values and protocol intent was statistically significant (p = 0.002). As expected, in diagnostic protocols, there was a statistically significant difference between CTDI_vol values of with and without contrast acquisitions (11.68 mGy vs 7.99 mGy, p = 0.009). In 13 out of 87 studies, the optimisation aim was not reported; in 2 papers, a clinical protocol was used; and in 11 works, a dose optimisation protocol was applied.

Conclusions

According to this review, the dose optimisation in PET/CT exams depends heavily on the correct implementation of the CT protocol. In addition to this, considering the latest technology advances (i.e. iterative algorithms development), we suggest a periodic quality control audit to stay updated on new clinical utility modalities and to achieve a shared standardisation of clinical protocols. In conclusion, this study pointed out the necessity to better identify the specific CT protocol use within PET/CT scans, taking into account the continuous development of new technologies.

EFFECTS OF THE SCAN RANGE ON RADIATION DOSE IN THE COMPUTED TOMOGRAPHY COMPONENT OF ONCOLOGY POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY

We performed phantom experiments to investigate radiation dose in the computed tomography component of oncology positron emission tomography/computed tomography in relation to the scan range. Computed tomography images of an anthropomorphic whole-body phantom were obtained from the head top to the feet, from the head top to the proximal thigh or from the skull base to the proximal thigh. Automatic exposure control using the posteroanterior and lateral scout images offered reasonable tube current modulation corresponding to the body thickness. However, when the posteroanterior scout alone was used, unexpectedly high current was applied in the head and upper chest. When effective dose was calculated on a region-by-region basis, it did not differ greatly irrespective of the scan range. In contrary, when effective dose was estimated simply by multiplying the scanner-derived dose-length product by a single conversion factor, estimates increased definitely with the scan range, indicating severe overestimation in whole-body imaging.

Hybrid Imaging in Head and Neck Sarcoidosis

Abstract: To determine the prevalence of head and neck sarcoidosis (HNS) and evaluate the role of hybrid molecular imaging in HNS. Between 2010 and 2018, 222 patients with chronic sarcoidosis and presence of prolonged symptoms of active disease were referred to FDG PET/CT. Active disease was found in 169 patients, and they were all screened for the presence of HNS. All patients underwent MDCT and assessment of the serum ACE level. Follow-up FDG PET/CT examination was done 19.84 ± 8.98 months after the baseline. HNS was present in 38 out of 169 patients. FDG uptake was present in: cervical lymph nodes (38/38), submandibular glands (2/38), cerebrum (2/38), and bone (1/38). The majority of patients had more than two locations of disease. After FDG PET/CT examination, therapy was changed in most patients. Fourteen patients returned to follow-up FDG PET/CT examination in order to assess the therapy response. PET/CT revealed active disease in 12 patients and complete remission in two patients. Follow-up ACE levels had no correlation with follow-up SUVmax level (ρ = -0.18, p = 0.77). FDG PET/CT can be useful in the detection of HNS and in the evaluation of the therapy response. It may replace the use of non-purposive mounds of insufficiently informative laboratory and radiological procedures.

Body Weight-Based Protocols During Whole Body FDG PET/CT Significantly Reduces Radiation Dose without Compromising Image Quality:Findings in a Large Cohort Study

RATIONALE AND OBJECTIVES

To investigate radiation dose reduction during whole body fluorodeoxyglucose (¹⁸F-FDG) positron emission tomographic (PET)/computed tomography (CT) by employing weight-based protocols.

MATERIALS AND METHODS

One thousand and twenty-eight patients were referred for ¹⁸F-FDG PET/CT study with one of two protocols: conventional protocol I; 120 kVp, 120 mAs, 0.5 second rotation time, pitch 0.8 mm/rot across all body weights; four-tier body weight protocol II all used 140 kVp, 0.75 seconds rotation time and pitch 0.8 mm/rot: Protocol A (≤60 kg): 35 mAs, Protocol B (61-80 kg): 50 mAs, Protocol C (81-100 kg): 65 mAs, and Protocol D: (>101 kg): 100 mAs. All protocols employed tube current modulation. Quantitative and qualitative image visual grading characteristics assessed image quality.

RESULTS

Patient demographics demonstrated no significant difference between each protocol except for patient weight in weight protocol IIB (p < 0.009). Mean effective dose in all protocols were significantly lower in Protocol B compared to A (p < 0.009). Contrast-to-noise ratio demonstrated no differences between each protocol (p < 0.21) except for weight protocol in protocol IIA (<60 kg, p = 0.035) with the visual grading characteristics demonstrating preference over protocol II compared to I.

CONCLUSION

Significant reduction in radiation dose can be achieved using patient-specific body weight-based protocols during whole-body ¹⁸F-FDG PET/CT without compromising image quality when employing weight-based protocols.

Significant dose reduction is feasible in FDG PET/CT protocols without compromising diagnostic quality

PURPOSE

To reduce the radiation dose to patients by optimizing oncological FDG PET/CT protocols.

METHODS

The baseline PET/CT protocol in our institution for oncological PET/CT examinations consisted of the administration of 5.18 MBq/kg of FDG and a CT acquisition with a reference current-time product of 120 mAs. In 2016, FDG activity was reduced to 4.44 and 3.70 MBq/kg and reference CT current-time-product was reduced to 100 and 80 mAs. 322 patients scanned with different protocols were retrospectively evaluated. For each patient, effective dose was calculated. The overall image quality was subjectively rated by the referring physician on a 4-point scale (IQ score: 1 excellent, 2 good, 3 poor but interpretable, 4 poor not interpretable). Image quality was quantitatively evaluated measuring noise in the liver.

RESULTS

CT Results: Effective dose was progressively reduced from 9.5 ± 2.8 to 8.0 ± 2.3 and 6.2 ± 1.5 mSv (p < 0.001). A mean dose reduction of 34.9% was achieved. There was a significant degradation of IQ score (p < 0.05) and noise (p < 0.001). Nevertheless, the number of poor quality studies (IQ score >2) did not increase. PET Results: Effective dose was gradually reduced from 6.5 ± 1.4 to 5.7 ± 1.3 and 5.0 ± 1.0 mSv (p < 0.001). Average dose reduction was 23.4%. IQ score (p < 0.05) and noise (p < 0.001) significantly degraded for lower activity protocols. However, all images with reduced activity were scored as interpretable (IQ score ≤ 3).

CONCLUSIONS

A significant radiation dose reduction of 28.7% was reached. Despite a slight reduction in image quality, the new regime was successfully implemented with readers reporting unchanged clinical confidence.

Effective dose estimation for oncological and neurological PET/CT procedures

BACKGROUND

The aim of this study was to retrospectively evaluate the patient effective dose (ED) for different PET/CT procedures performed with a variety of PET radiopharmaceutical compounds. PET/CT studies of 210 patients were reviewed including Torso (n = 123), Whole body (WB) (n = 36), Head and Neck Tumor (HNT) (n = 10), and Brain (n = 41) protocols with 18FDG (n = 170), 11C-CHOL (n = 10), 18FDOPA (n = 10), 11C-MET (n = 10), and 18F-florbetapir (n = 10). ED was calculated using conversion factors applied to the radiotracer activity and to the CT dose-length product.

RESULTS

Total ED (mean ± SD) for Torso-11C-CHOL, Torso-18FDG, WB-18FDG, and HNT-18FDG protocols were 13.5 ± 2.2, 16.5 ± 4.5, 20.0 ± 5.6, and 15.4 ± 2.8 mSv, respectively, where CT represented 77, 62, 69, and 63% of the protocol ED, respectively. For 18FDG, 18FDOPA, 11C-MET, and 18F-florbetapir brain PET/CT studies, ED values (mean ± SD) were 6.4 ± 0.6, 4.6 ± 0.4, 5.2 ± 0.5, and 9.1 ± 0.4 mSv, respectively, and the corresponding CT contributions were 11, 14, 23, and 26%, respectively. In 18FDG PET/CT, variations in scan length and arm position produced significant differences in CT ED (p < 0.01). For dual-time-point imaging, the CT ED (mean ± SD) for the delayed scan was 3.8 ± 1.5 mSv.

CONCLUSIONS

The mean ED for body and brain PET/CT protocols with different radiopharmaceuticals ranged between 4.6 and 20.0 mSv. The major contributor to total ED for body protocols is CT, whereas for brain studies, it is the PET radiopharmaceutical.

Impact of hybrid molecular imaging in retroperitoneal fibrosis: a systematic review

The aim of this article was to critically assess the usefulness of hybrid molecular imaging (FDG PET/CT and FDG PET/MR) procedures in the evaluation of inflammatory activity in retroperitoneal fibrosis (RPF). A systematic review of the literature was performed using PubMed without timeline restriction and using the following keywords: retroperitoneal fibrosis, disease activity, diagnostic techniques, PET/CT, PET/MR. We evaluated full text articles written in the English language. Case reports, review articles or editorials and articles not in the field of interest of this review were excluded. Nine articles comprising a total of 186 patients met the inclusion criteria and were included and described in this systematic review. The new hybrid molecular imaging methods give promising results in the evaluation of the activity of the disease, quantification and prediction of therapeutic response and in tailoring medical therapy in RPF. FDG PET/CT can be a valuable tool in detecting disease activity, particularly in asymptomatic patients with RPF with acute phase reactant increase. Hybrid imaging can predict therapy response outcome and the best time for stent removal. Although PET/MR has potential advantage in small lesions and has reduced radiation exposure in comparison to PET/CT, PET quantification parameters have potentially higher diagnostic value over MR parameters in the evaluation of RPF. Acute phase reactants alone may not be reliable for the management and follow-up assessment of the disease. Hybrid imaging in RFP could be more comfortable, more accurate, with less radiation burden than different separate imaging studies acquired at different points in time.

A JAFROC study of nodule detection performance in CT images of a thorax acquired during PET/CT

PURPOSE

Two types of CT images (modalities) are acquired in PET/CT: for attenuation correction (AC) and diagnosis. The purpose of the study was to compare nodule detection and localization performance between these two modalities.

METHODS

CT images, using both modalities, of an anthropomorphic chest phantom containing zero or more simulated spherical nodules of 5, 8, 10 and 12 mm diameters and contrasts -800, -630 and 100 HU were acquired. An observer performance study using nine observers interpreting 45 normal (zero nodules) images and 47 abnormal images (1-3 nodules; average 1.26) was conducted using the free-response receiver operating characteristic (FROC) paradigm. Data were analysed using an R software package implemented jackknife alternative FROC (JAFROC) analysis. Both empirical areas under the equally weighted AFROC curve (wAFROC) and under the highest rating inferred ROC (HR-ROC) curve were used as figures of merit (FOM). To control the probability of Type I error test alpha was set at 0.05.

RESULTS

Nodule detection as measured by either FOM was significantly better on the diagnostic quality images (2nd modality), irrespective of the method of analysis, [reader averaged inter-modality wAFROC FOM difference = -0.07 (-0.11,-0.04); reader averaged inter-modality HR-ROC FOM difference = -0.05 (-0.09, -0.01)].

CONCLUSION

Nodule detection was statistically worse on images acquired for AC; suggesting that images acquired for AC should not be used to evaluate pulmonary pathology.

The Advents of Hybrid Imaging Modalities: A New Era in Neuroimaging Applications

Hybrid Imaging modalities have shown great potential in medical imaging and diagnosis. A more comprehensive and targeted view of neurological disorders can be achieved by blending the anatomical and functional perspectives through hybridization. With consistently improving technologies, there have been many developments in fused imaging techniques over the past few decades. This article provides an overview of various bimodal and trimodal hybrid imaging techniques being developed and explored for neuroimaging applications. Recent advancements and potentials are discussed for single photon emission computed tomography-computed tomography (SPECT-CT), positron emission tomography-CT (PET-CT), PET-magnetic resonance imaging (PET-MRI), electroencephalography-functional magnetic resonance imaging (EEG-fMRI), magnetoencephalography-fMRI (MEG-fMRI), EEG-near-infrared spectroscopy (EEG-NIRS), magnetic resonance-PET-EEG (MR-PET-EEG) and MR-PET-CT in the perspective of neuroimaging. A comparison of these hybrid approaches is provided on a single platform to analyze their performance on the basis of several common factors essential for imaging and analyzing neurological disorders and in vivo molecular processes. This article also provides an overview of recently developed advanced imaging technologies that are being hybridized with other imaging modalities and being explored as potential techniques for neuroscience. Novel approaches and clinical applications of hybrid neuroimaging are anticipated with inclusion of new technologies, better sensing capabilities, multimodal probes, and improved hybridization.

Diagnostic Reference Levels of CT Radiation Dose in Whole-Body PET/CT

The role of CT in PET/CT imaging includes acquisition techniques for diagnostic, anatomic localization, and attenuation correction purposes. Diagnostic reference levels of the volumetric CT dose index (CTDIvol) are available for dedicated CT procedures on selected body regions, but similar reference levels for whole-body CT used in PET/CT examinations are limited. This work reports CTDIvol values from sites that conduct whole-body oncologic PET/CT examinations and participated in the scanner validation program of the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network.

METHODS

From 2010 to 2014, a total of 154 sites submitted CT acquisition parameters used in their clinical (18)F-FDG PET/CT oncology protocols. From these parameters, the CTDIvol was estimated using the ImPACT CTDI dosimetry tables. Histograms of CTDIvol values were created for each year, and descriptive statistics, including mean, median, and 75th percentile, were reported. Repeated-measures ANOVA was performed to determine whether significant differences occurred between reporting years.

RESULTS

A wide range of technical parameters was reported, most notably in tube current. Between 2010 and 2014, the median CTDIvol ranged from 4.9 to 6.2 mGy and the 75th percentile from 9.7 to 10.2 mGy. There was no significant change in CTDIvol between reporting years (repeated-measures ANOVA, P = 0.985).

CONCLUSION

The 75th percentile CTDIvol reported in this work was 9.8 mGy averaged over all reporting years. These data provide a resource for establishing CTDIvol reference values specific to performing CT in PET/CT whole-body examinations. The wide ranges of CT acquisition parameters reported by sites suggest that CTDIvol reference levels may be beneficial for optimization of CT protocols.

Patient doses from PET-CT procedures

Positron emission tomography (PET) was installed for the first time in Bulgaria in 2009, and nowadays two hybrid PET-computed tomography (CT) systems are in operation. The aim of this work is to estimate patient doses from PET-CT procedures and to explore potential for optimisation. Data were retrospectively collected for 50 patients examined with the system Philips Gemini TF and for 58 patients examined with the system GE Discovery 600. Whole-body examinations with radiopharmaceutical (18)F-2-fluoro-2-deoxy-D-glucose (FDG) were performed on all patients. Patient effective doses from the CT component of the examination were calculated with CT Expo software and compared with doses estimated applying the National Radiological Protection Board (NRPB) conversion coefficients. Effective doses from the PET component were calculated applying the ICRP 80 conversion coefficients. For the first system, average effective doses from CT component were 8.0 and 8.9 mSv, applying CT Expo and NRPB coefficients, respectively, and 4.9 mSv from PET component. For the second system, the corresponding values were 7.8, 8.7 and 5.9 mSv. These results for patient effective doses are relatively lower or comparable to other similar surveys. Reasons for the observed differences are analysed and presented.

Dose optimization in nuclear medicine

The practice of diagnostic nuclear medicine involves the use of ionizing radiation, and thus the potential risk associated with such exposure must be weighed against the benefits to the patient. This requires that the right test with the right dose be administered to the right patient at the right time. Therefore the procedure should be performed only if it is deemed most appropriate for the clinical question being asked. If appropriate, the procedure should be performed in the most optimum manner that keeps the radiation dose to the patient as low as possible while providing the patient's clinician with information that is needed to devise a plan of medical management. If this approach is followed, the benefits to the patient will far outweigh the small potential risks associate with the procedure. This article discusses these issues, particularly in the context of cardiovascular nuclear medicine and hybrid imaging including PET/CT and SPECT/CT.